



**CONSOLIDATED RESULTS
ACCUMULATED TO THIRD QUARTER 2007**

- Revenues have reached €114,836k, which represents an increase of 15.8% over the same period of 2006.
- EBITDA has increased by 116.7% to €18,514k.
- EBIT has risen to a profit of €12,040k, 332.8% higher than the same period previous year.
- Net income has reached a profit of €4,835k compared to a loss of €718 in 2006.

Revenues by country



EBITDA by country



Relevant Information

Spain

1. There are 49 operating clinics open in Spain by 30th September 2007.
2. During November we will move to new locations in the cities of Cordoba, La Coruña and Zaragoza. The works in the clinic of Alcala de Henares continue and they will finish by the beginning of 2008.

Portugal

1. We continue having a strong growth in this country, with sales growth of 23.8% up to the third quarter.

United Kingdom

1. After the openings of the clinic of Liverpool in July and Nottingham in September, the number of clinics opened by the end of the third quarter is 17. During October we opened a new clinic in Edinburgh together with D&A, so currently the number of opened clinics is 18.
2. Works and search of locations continue for the opening of 8 new ophthalmology clinics in 2008. Two of these clinics were expected to be opened in 2007, but finally will be opened in January 2008.
3. The growth of the UK's business continues accelerating, with sales growth of 37.1% up to the third quarter.

Italy

1. The revenues in the third quarter of 2007 with 17 clinics in 17 cities have been similar to the revenues achieved the previous year with 44 clinics in 23 cities.
2. Sales continue growing, with a like for like growth of 34.1% up to the third quarter of 2007, and a like for like growth of 65.2% in the third quarter.
3. The increasing volume of calls received and the conversion of these into consultations allow us to forecast the continuity in growth of our sales.

The purpose of this document is informative and does not represent any offer or invitation to investors to buy or subscribe to shares of any kind issued by any of the companies mentioned, and in no way constitutes the basis of any other document or any commitment.

This results report has been compiled by the Company with the sole aim of being used for the presentation of the Group's results for the third quarter of 2007.

The information collected in this document can contain statements on intentions, estimates and future projections. All these statements, except the ones based on historical data, are statements to future, including among others, the ones related to our net investment, business strategy, management plans and goals of future operations. The mentioned intentions, estimates and future projections are affected, by their nature, by risks and uncertainties that could determine that the real outcome does not correspond with them.

The risks and uncertainties that could potentially affect the information included in this note are difficult to predict. The Company takes on no obligation to review or to publicly update these statements should any unforeseen changes or events take place which could affect them.

Nevertheless, the Company with the documents that are submitted to the Spanish 'Comisión Nacional del Mercado de Valores' provides information about the events that may affect the statements on future facts, business and financial results of the Group, and invites all the people interested to consult it.

1. Consolidated Profit and Loss Account

Corporación Dermoestética € Thousand	3Q		Var %	YTD 3Q		Var %
	2007	2006		2007	2006	
Net Sales	35,455	31,776	11,6%	114,836	99,182	15,8%
COS	(8,500)	(6,634)	28,1%	(26,023)	(21,287)	22,2%
GROSS MARGIN	26,955	25,142	7,2%	88,813	77,895	14,0%
	76,0%	79,1%		77,3%	78,5%	
Other operating expenses	(23,501)	(24,215)	-2,9%	(70,299)	(69,352)	1,4%
EBITDA	3,454	927	272,6%	18,514	8,543	116,7%
	9,7%	2,9%		16,1%	8,6%	
Depreciation	(2,169)	(1,990)	9,0%	(6,474)	(5,761)	12,4%
EBIT	1,285	(1,063)	-220,9%	12,040	2,782	332,8%
	3,6%	-3,3%		10,5%	2,8%	
Financial results	(1,886)	(982)	92,1%	(5,267)	(3,373)	56,2%
Corporate tax	(93)	1,030	-109,0%	(1,938)	(127)	N/A
NET INCOME	(694)	(1,015)	-31,7%	4,835	(718)	N/A
	-2,0%	-3,2%		4,2%	-0,7%	

1.1 Net Sales

Up to the third quarter of 2007 revenues have increased by 15.8% compared to the same period of 2006, totalling €114,836k. Within this growth Spain has contributed 3.2%, Portugal 23.8%, UK 37.1% and Italy has nearly reached same sales of previous year from €4,753k to €4,687k, with less open clinics.

The like for like growths up to the third quarter have been:

Like for like Sales Growth	YTD 3Q
Spain	(0.6)%
Portugal	18.8%
United Kingdom	31.5%
Italy	34.1%


1.2 Gross Margin

Up to the third quarter of 2007 the gross margin has been €88,813k, having being €77,895k in the same period of 2006. This means that there has been a small decrease in the gross margin as percentage of the net sales. This decrease has been caused by the change in the selling-mix, and also because of the use of disposable consumables in the refractive surgery.

1.3 EBITDA and EBIT

The EBITDA has increased by 116.7%, compared with the same period of 2006, up to €18,514k. This increase is due to the strong growth in sales and the improvement in margins in UK and Portugal, and to the reduction in operating costs in Italy after the reorganisation carried out at the end of last year.

EBITDA evolution by country



The EBIT is €12,040k, 332.8% higher than the same period of the previous year where we had €2,782k.

1.4 Net Income

The net income rises from losses of €(718)k up to the third quarter of 2006, to €4,835k of profit at the end of the first nine months of 2007.

2. Consolidated Balance Sheet and Net Investment

Consolidated Balance Sheet

Corporación Dermoestética Thousand €	2007	%	2006	%	Variación 07 / 06
ASSETS					
Fixed assets					
Property, plant and equipment	45,037	40%	45,634	34%	(597)
Intangible assets					
Goodwill	16,438	15%	18,390	14%	(1,952) (*)
Other intangible assets	21,168	19%	21,222	16%	(54) (*)
Others	6,499	6%	18,139	13%	(11,640) (**)
	89,142	80%	103,385	76%	(14,243)
Current Assets					
Cash and equivalents	7,575	7%	17,522	13%	(9,947)
Debtors	3,145	3%	2,352	2%	793
Inventory	5,493	5%	4,651	3%	842
Others	6,348	6%	7,754	6%	(1,406)
	22,561	20%	32,279	24%	(9,718)
Total assets	111,703	100%	135,664	100%	(23,961)
LIABILITIES					
Shareholders' Equity					
Paid-in Capital	3,989	4%	3,989	3%	-
Reserves	12,401	11%	12,401	9%	-
Retained Earnings	14,400	13%	8,230	6%	6,170
Translation differences	(179)	0%	-	0%	(179)
Treasury/reacquired stocks	(3,536)	-3%	-	0%	(3,536) (***)
	27,075	24%	24,620	18%	2,455
Long term Liabilities					
Debts with credit institutions	28,127	25%	35,839	26%	(7,712)
Liabilities from deferred taxes	6,390	6%	18,922	14%	(12,532) (**)
Provisions	3,745	3%	7,088	5%	(3,343)
Other long term Liabilities	1,355	1%	5,130	4%	(3,775)
	39,617	35%	66,979	49%	(27,362)
Short term Liabilities					
Debts with credit institutions	8,225	7%	5,459	4%	2,766
Commercial creditors	29,843	27%	30,703	23%	(860)
Other short term liabilities	6,943	6%	7,903	6%	(960)
	45,011	40%	44,065	32%	946
Total Liabilities	111,703	100%	135,664	100%	(23,961)

(*) By the end of 2006 the Group re-estimated the amount of its "Goodwill" in accordance with IFRS 8, reassigning €18,194k to the commercial brand of Ultralase.

(**) By the end of 2006, the company adopted the decision of not registering the tax credits from the losses of its subsidiaries, cancelling all its tax credit against "Liabilities from deferred taxes".

(***) At the end of 2006 and during 2007, shares of the parent company have been purchased increasing the value of the total "Treasury/reacquired stocks" to €3,536k (404,957 shares), what represents 1.0% of its share capital.

Net investment

Financial Position

Thousand €

	3Q 2007	3Q 2006
Long Term Debt with credit institutions	28,127	35,839
Short Term Debt with credit institutions	8,225	5,459
Long Term Debts with previous shareholders of Ultralase	154	3,913
Short Term Debts with previous shareholders of Ultralase	-	2,005
Gross Financial debt	36,506	47,216
Cash and equivalents	(7,575)	(17,522)
Net Financial debt	28,931	29,694

Keeping with the Group's general policy, we expect to continue self-financing our international expansion or any other new opportunity with the cash-flow generated by the Group's ordinary activities, when possible.